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ABSTRACT
In the past few years, compelling data have shown the potential crosstalk between dysbiosis of gut microbiota (GM) 
and impairment of systemic immune system. Since then, ideas on how GM partake in autoimmune conditions was 
put forward. Although genetic variability have been proven to contribute towards the pathogenesis of autoimmune 
conditions, epigenetics control have gained interest among researchers. Current review highlights the crosstalk be-
tween autoimmune conditions and GM and its potential regulatory mechanisms. Convincing data from existing 
literature help in paving ways for more well-defined species in the future studies. The studies should focus on identi-
fying the distinct species involve in different types of autoimmune diseases and their definitive role in autoimmunity. 
Ultimately, these data can be used for the advancement of therapeutic approach in personalized medicine.  
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INTRODUCTION
The immune system of vertebrae provides systematic 
approach to combat insults from the inside and outside 
the body. When immune system go awry, deregulated 
immune response may result in autoimmunity, a 
condition where the immune cells destruct body own 
cells. The pathogenesis of autoimmune condition 
is multifactorial where genetic predisposition and 
epigenetics regulation herald changes into uncontrolled 
immune responses, giving rise to the formation of 
autoantibodies damaging one’s own cell. The presence 
of pathogenic autoantibodies are highly specific in 
organ-specific autoimmune diseases such as thyroiditis, 
type 1 diabetes and primary biliary cirrhosis. Whereas 
in systemic autoimmune diseases like systemic lupus, 
the production of autoantibodies is less specific and 
directed against multiple organs (1). 
Interestingly in recent years, it has becoming a common 
notion that host immunity has co-evolved with the GM 
due to their long co-existence mutualistic relationship; 
and this justified the homeostasis between these 
components are fundamental to both the gut integrity 
and healthy immune system. The first step towards 
understanding the symbiotic relationships of the GM 
with their hosts is to characterize these community 
at baseline healthy and disease states (2). Mounting 
evidences suggested that dysbiosis - an imbalance or 
maladaptation of gut microbiome communities would 
affect the host bodily functions. Perturbations in gut 
microbiome have now been linked with disease states 
such as cardiovascular disease (3, 4) obesity (5, 6) 
several type of cancers (7, 8) and inflammatory bowel 
disease (9).
 
ESSENTIAL MICROBES IN HUMAN HEALTH 
MAINTENANCE
Overall temporal stability of the core microbial 
community within healthy individuals conferred 
health benefits relating to pathogen protection, host 
metabolism, immune modulation, and food digestion 
and nutrient absorption (2, 10) However, a number 
of factors including decline in the physiology of the 
gastrointestinal tract due to ageing, antibiotic exposure, 
diet, and environmental factors can cause changes in 
composition as well as function (11, 12). Furthermore, 
dysbiosis observed in autoimmune diseases is associated 
with inflammation during infection, reduced bacteria 
function and diversity, bacterial translocation, impaired 
epithelial barrier, and declined regulatory T cells in 
the gut mucosa (13). Hence, gut microbiota and their 
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metabolites could regulate immune cells and cytokine 
release via epigenetic modifications, suggesting their 
possible role in autoimmune disease development (14).
Understanding how the GM affect health and disease 
requires a shift in focus from individual pathogens, 
towards an ecological approach considering the 
community as a whole. Mounting studies showed 
that manipulating GM via probiotics and prebiotics 
interventions could be useful to improve immunity in 
humans and animal models. To this end, is therefore 
logical that modulating the gut microbiome should be 
considered as a therapeutic strategy to treat the diseases 
via supplementation with probiotics (14, 15, 16, 17), 
the diet or the use of prebiotics (18). Remarkebly, 
polyphenol-enriched diet modulates mucosal immune 
responses (19) and dietary cinnamaldehyde enhances 
acquisition of specific antibodies in animal studies (20). 
Moreover, reconstitution of bacterial populations by 
fecal transplantation or by employing antimicrobials to 
eliminate pathogens or manipulate the GM in a way that 
will benefit host health (21). 
CROSSTALK OF GM ON IMMUNE SYSTEM
The fact that bacteria in the gut interact with the host 
immune system is now well accepted and illustrated by 
in vitro and in vivo experiments. And this has becoming 
progressively supported by human intervention trials 
(22).  The symbiotic relationship provides beneficial 
outcomes to the host by metabolizing ingested 
nutrients, drugs and substances, maintenance of gut 
mucosal microenvironments and protection against 
pathobionts. Also, they produce beneficial outcome to 
the host by fermentation and digestion carbohydrates 
into absorbable short-chain fatty acids (SCFAs), vitamin 
synthesis as well as regulating the gut-associated 
immune cells (14). GM are essential for the complete 
development of the immune system, representing a 
binary network in which the microbiota interact with 
the host, providing important immune and physiologic 
function and conversely the bacteria protect themselves 
from host immune defence (23). Thus, GM play an 
important role in maintaining normal function of 
systemic immune system by regulating gut immune 
system as described in Figure 1.
Bassaganya-Riera and colleagues have demonstrated 
the manipulation of gut probiotics and their metabolites 
has potentially alleviates IBD in mouse models (24). In 
a randomized control trial performed among colicky 
infants, oral supplement of Lactobacillus reuteri for 
one month have reduced the crying time as opposed to 
placebo by reducing Th17 cells and promoting Foxp3+ 
cells thus suppressing inflammatory reactions (25). In 
fact, previous work has attested that the metabolism 
of GM modulates serotonin-producing cells which in 
turn regulates gastrointestinal physiology (26). These 
metabolites are further appraised as immune regulators 
shown by induction of tolerance in food-allergy models 
(27) and improved gut symbionts in children with anti-
islet autoantibody (28).  Interestingly, supplement of 
probiotics in addition to breastfeeding has improved the 
composition of GM in infants treated with antibiotics 
and caesarean-birth infants by restoring the microbial 
metabolic capacity of bifidobacteria (29). This 
significantly contribute to better immune function in 
compromised caesarean-birth infant as they are prone to 
develop metabolic diseases and autoimmunity (30,31). 
Meanwhile, oral tolerance induced by GM controlled 
the development of food allergy in mice models fed 
with high-fibre diet (27). It was shown that the levels of 
CD103+ dendritic cells (DC) is higher in allergy-induced 
mice fed with high-fibre diet as opposed to zero-fibre 
diet (27). Modulation of 103+ DC is important as they 
possess the capacity to induce naïve T cells into iTreg 
cells in MLN to minimize adverse pro-inflammatory 
responses (32). Moreover, microbial metabolites 
repertoire has recently been compiled thus intrigued 
researchers to further investigate their roles on the 
immune system. One of the compounds that recently 
came to limelight are tryptophan-derived metabolites 
which is known to be the ligand for aryl hydrocarbon 
receptor (AHR). Activation of AHR leads to the activation 
of anti-inflammatory responses via IL-22 signalling 
pathway (33, 34). On more detailed understanding as 
how GM regulate host immune functions, although not 
many, a few studies have already revealed molecular 
mechanisms involved in mediating immune responses 
in animal models. One of the proposed mechanism is 
via G-protein coupled receptor 43 (GPR43) on epithelial 
cells and GPR109a on immune cells which serve as 
receptors for SFCA. Binding of GPR43 receptors to 
SCFA produced by GM alleviated colitis and allergy 
in mouse models, suggesting the metabolite of GM as 
one of mediators in immune regulation (27, 35). A study 
revealed the capacity of GM to regulate distant organs 
Figure 1: Gut microbiota modulates the intestinal immune 
homeostasis by their metabolites. CD103+ DCs resides in the 
lamina propria interact with CX3CR1+ macrophages which are capa-
ble to reach up for antigens in the lumen and presenting them to the 
DCs for activation. Activated CD103+ DCs will further activate T cells 
including its subset Foxp3+ T-regulatory (Foxp3+Treg) cells. Interaction 
between CD103+ DCs and Foxp3+ Treg cells is important to determine 
the tolerance levels to certain food antigens. Thus, depending on the 
levels of activation and exposure of particular antigens, the interaction 
between CD103+/Foxp3 Treg cells will eventually lead to peripheral 
tolerance via IL-10 mechanism. 
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such as pancreas from developing autoimmune diabetes 
by promoting β-defensin 14 expression by pancreatic 
endocrine cells (36). The distal response is mediated by 
metabolites of GM and act as AHR ligands and butyrate, 
which in turn stimulate IL-22 secretion by pancreatic 
innate lymphoid cells (36). 
A retrospective analysis identified the use of antibiotics 
in early life is associated with subjects diagnosed with 
inflammatory bowel diseases (IBD) in their childhood 
and thus promoting the possible role of antibiotics in 
altering the compositional structure of commensal 
microbiota (37). In addition, a gut model consisting 
evolutionarily-conserved mucosal associated invariant T 
cells known as monomorphic major histocompatibility 
complex class I-related molecules (MR1) have showed 
that they require the presence of commensal microbiota 
for expansion in lamina propria (38). Interestingly, 
more reports have shown that the established mutual 
agreement between several strains of Lactobacillus spp 
results in restoration of T-regulatory cells and inactivation 
of T cell reactivity in lamina propria of animal models 
(39, 40, 41). DC-derived from this anatomical sites 
have been shown to be able to reach luminal bacteria 
through gap junction during low degree of physiological 
gut leakiness (42, 43), suggesting the potential of 
pathogenic antigen presentation originally from gut 
lumen to further drained into nearby mesenteric lymph 
nodes for clearance. Comprehensive investigations 
of host cell responses to probiotics display distinct 
pathogen-associated molecular pattern (PAMP) since 
then has been put forward. Haller and Jobin (2004) 
mentioned that the role of Bifidobacterium animalis 
and E. faecalis inhibit  NF-jB activity and IL-6 gene 
expression in intestinal epithelial cells (IEC) via pattern 
recognition receptor stability, chromatin remodelling 
and modulation of phosphatase activity (44). 
Intriguingly, the fact that orally ingested probiotics persist 
and permanently reside in the intestinal lumen is remain 
elusive. Despite, a number of studies showed that ingested 
probiotics only transiently persist in the intestine during 
“dosing” period which is yet to be defined for its relative 
duration under various circumstances (22, 45, 46, 47). 
Huttenhower and colleagues (2012) and Gianchecchi 
and Fierabracci (2019) summarized that the colonization 
of GM is a dynamic, complex and gradual process with 
no random events which continuously evolve (48, 49). 
This is demonstrated by the fact that their composition 
of humans and other mammals consist of elevated levels 
of conservation of the same phylum (48). 
GM INVOLVEMENT IN AUTOIMMUNE CONDITIONS
A healthy immune system is essential for mounting an 
effective immune response against foreign antigen in 
order to eliminate any potential pathogenic infection but 
still remain tolerant against autoreactive immune cells. 
However, autoimmune diseases are established when 
immune tolerance is breached by overexuberant and 
unwanted immune responses, which may contribute to 
a lower quality of life and raise health concern. In fact, 
recent epidemiological data have suggested that the 
incidence and prevalence of autoimmune diseases is 
increasing worldwide (50), which provide an insight that 
environmental factors (e.g. dietary changes and overuse 
of antibiotics that leads to dysbiosis) might be more 
important than we initially thought in the pathogenesis 
of autoimmune disease . In this review, we aimed to 
highlight the effect of the gut microbiota in autoimmune 
disease pathogenesis by summarising data from both 
murine models and human case study.
Probably the most puzzling part is how GM controlling 
intestinal regulation may affect systemic immune 
response and organ-specific autoimmune diseases. 
Indeed, with trillions of GM in adult human, it is possible 
that any changes in the gut composition or function may 
alter immune responses in host physiology (24). When 
SCFA production by gut microbiome are altered as a 
result of dysbiosis, the intestinal barrier may be disrupted 
and permeabilise the intestinal epithelium, leading to 
infiltration of bacteria into the mesenteric lymph node 
(MLN) (27, 36, 51). As a result, the intestinal dendritic 
cells at the surface mucosa is activated more frequently 
(due to more bacteria breaching the intestinal barrier) 
and more T cells are differentiated, which would result 
in the over reactivity T cells for the establishment of 
autoimmune conditions (33, 36). Indeed, the leaky gut 
hypothesis propose that bacterial translocation could 
be potentially increased, leading to elevation of cross-
antigen presentation between self and nonself-antigen 
recognition and result in the exacerbation of extra-
intestinal autoimmune diseases like T1D, SLE and atopic 
dermatitis (36, 51, 52, 53, 54, 55) (Figure 2). 
The existence of gastrointestinal-related autoantibodies 
in different types of autoimmune diseases may suggest 
the crosstalk between GM regulation and onset of 
autoantibodies formation. The most studied GI-related 
antibodies include anti-gliadin antibodies (AGA) and 
anti-tissue transglutaminase (tTG) antibodies. These 
Figure 2: Imbalance in the gut microbiota composition leads 
to the loss of microbial metabolites that changes the func-
tion of intestinal epithelial cells. This affect the physiological and 
metabolism of normal lining by reducing mucus production, increase 
pathogenic microbes and toxins into underlying tissues, and stimulate 
mucosal inflammation by inhibiting IL-22 production and reduce im-
mune tolerance
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antibodies have been titred in patients with multiple 
sclerosis (56, 57, 58) and inflammatory myopathies (59). 
This in fact is shown clinically by celiac disease as an 
extra-pancreatic manifestation of type 1 diabetes (51). 
Similarly, the co-existence of ulcerative colitis in SLE 
patients is commonly underdiagnosed (60). 
More reports on established relationship between 
dysbiosis and autoimmune diseases such as rheumatoid 
arthritis (61), systemic lupus erythematosus (SLE) (51, 
52, 62), type 1 diabetes (T1D) (28) (, primary Sjogren 
Syndrome (pSS) (63), multiple sclerosis (MS) (64) 
and also atopic dermatitis (AD) (55) are extensively 
discussed in recent years. The intertwined relationship 
between gut symbionts and autoimmune disease can 
be seen as the microbiome in patients with newly-onset 
rheumatoid arthritis (RA) is enriched by the pathobiont 
Prevotella copri (65) whereas increasing abundance in 
Methanobrevibacter and Akkermansia and a reduction 
in Butyricimonas is observed in human subjects with 
multiple sclerosis (MS) (64). Following that, several 
recent cohort studies have demonstrated that the gut 
microbiota is less diverse in new-borns with AD in 
conjunction with reduced amounts of Bifidobacterium 
and Bacteroides but elevated Enterobacteriaceae levels 
(55, 66, 67). Given the fact that Bifidobacterium exhibit 
an anti-inflammatory effect and are able to alleviate 
Th2 immunity, one can imply that the gut microbiome 
with Bifidobacterium deficiency are more susceptible to 
developing AD (68, 69). Thus, prescription of probiotics 
regimens containing Bifidobacteria and another 
commonly used species Lactobacilli could shed light 
into the prevention and treatment of AD, although the 
timing and dose of administration still warrants further 
investigation (68, 69). However, the hypothesis that 
each autoimmune disease is resulted from the presence 
of a single genera may be an over-simplication of the 
entire picture (70). A study conducted in children 
with anti-islet cell autoantibodies suggested that the 
sophisticated networks between each bacterium may 
also be crucial in the establishment of the anti-islet 
cell autoimmunity, which may progress into the pre-
clinical stage for T1D (70). Ideally, molecular protein 
possessed by diabetogenic microbes (Mgt protein of 
Leptotrichia goodfellowii found in GM) shares structural 
similarities with self-antigen in the host (islet-specific 
glucose-6-phosphatase-related protein (IGRP) found in 
pancreas) (44), which can lead to the acceleration of 
T1D pathogenesis via molecular mimicry mechanism, 
as previously reported (42, 43, 44, 55, 71,72).
Besides, an association between dysbiosis and IBD 
has also been reported earlier in murine model by 
Nagalingam and colleagues (73). The interrelationship 
between RA and celiac disease (CD) suggesting the 
potential crosstalk between gut-joint pathogenesis 
(74). GM composition of buccal mucosa from pSS 
patients are distinctly different with healthy control in 
such that the microbiome of pSS patients consist of a 
higher Firmicutes/Proteobacteria ratio when compared 
to healthy control (54). Similarly, in induced-dysbiosis 
of pSS mouse models have shown a reduction in the 
microbiome diversity and accelerate the establishment 
of autoimmune mucosal inflammation. In specific, the 
stool samples from antibody-treated mice have shown 
a reduction in Clostridium genus while a pilot study 
involving pSS patients also shown a significant loss in 
Faecalibacterium among the fecal microbiome (54).
Furthermore, the putative role of gut microbiome in 
structuring autoimmunity has been demonstrated by 
Wu and colleagues (2010) on segmented filamentous 
bacteria (SFB) as a general immunomodulator in which 
enhance the establishment of autoimmune arthritis (75) 
and EAE (76), albeit protecting from T1D pathogenesis 
(77). Notably, a germ-free, IL-1 receptor antagonist 
deficient (GF IL-1Rn-/-) mouse model that represent a 
spontaneous T-cell mediated arthritis failed to develop 
autoimmune arthritis but subsequent mono-colonisation 
of Lactobacillus bifidus are able to restore the disease 
(75, 78). Another reports have shown that three 
microorganisms, including Dialister invisus, Gemella 
sanguinis, and Bifidobacterium longum, are correlated 
with compromised gut integrity and higher intestinal 
permeability eventually elevated T1D risk (71,72,79,80). 
Nonetheless, Tryptophan (Trp) metabolism by GM 
(e.g. Clostridium sporogenes, Bifidobacteria infantis 
and Lactobacillus reuteri) can also contribute to the 
homeostasis of intestinal immune activation and also 
tolerance (81). Similarly, Lactobacillus reuteri modulate 
inflammation at different body sites (intestinal and 
extraintestinal) by regulating the microbiota-adenosine-
inosine receptor 2A (A2A) axis and alleviating the pro-
inflammatory Th1 and Th2 cell differentiation in Scurfy 
model to resemble SLE in human (82). Altogether, these 
studies propose that our gut microbiome is one of the 
dictators in shaping autoimmune diseases outcome and 
further investigations are required in order to explore the 
microbiota/immunity crosstalk thoroughly (83).
CONCLUSION
Compelling data have shown that GM are closely liaised 
with various types of autoimmune diseases in the form of 
dysbiosis- alteration of individual species and/or global 
communities of the GM (dysbiosis) which can give 
rise to different outcomes of autoimmune conditions. 
Certainly, gut microbiome could possibly be applied 
as a biomarker for autoimmune diseases prediction. 
Furthermore, the knowledge can also be manifested into 
probiotics enhancement as precision editing of GM may 
be utilized to reverse autoimmune conditions.
Although encouraging, these reports need to be 
correspond to the demands for scientific proves on how 
these microbial colony imbalance lead to dysregulation 
of immune systems. Further studies are also necessary 
to justify the role of ingested probiotics as immune 
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modulators during their “transit” stay in the gut. 
Furthermore, prescription of lactobacillus probiotics in 
some circumstances may be unfavourable in infants, 
leading to the progression of D-lactic acidosis (84). 
These results have shed like into considerations of 
administrating the same probiotics regimen into human 
body as “one probiotic will not fit all”. Therefore, further 
researches are much needed in order to delineate the 
optimal choice of probiotic composition for each 
disease entity studies. 
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